Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | NMUR2 | Q9GZQ4 | 6/20 | 0.48 |
| ▸ | NMUR1 | Q9HB89 | 6/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.45 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.45 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506913 | 0.98 | MAPK8 (0.50) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL29601373 | 0.96 | MAPK8 (0.52) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL29506912 | 0.96 | MAPK8 (0.52) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL31049835 | 0.95 | MAPK8 (0.48) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL29634954 | 0.94 | CALCRL (0.51) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL31490515 | 0.93 | MAPK8 (0.54) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL31049840 | 0.92 | MAPK8 (0.47) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL31490504 | 0.91 | MAPK8 (0.52) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL29506907 | 0.91 | SLC6A2 (0.53) | MAPK8MAPK9MAPK10NMUR2NMUR1 | |
| SCHEMBL31049845 | 0.90 | MAPK8 (0.45) | MAPK8MAPK9MAPK10NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117736266-A | Preparation method and application of fibroblast activation protein specific diagnosis and treatment integrated probe | 上海交通大学医学院附属仁济医院 | 2024-03-22 | — | — | CN | claimed |
| US-20260061086-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4653451-A1 | POLYPEPTIDE COMPOUND AND USE THEREOF | Chengdu New Radiomedicine Technology Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-12427210-B2 | Compounds comprising a fibroblast activation protein ligand and use thereof | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-30 | — | — | US | disclosed |
| EP-4517326-A2 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2025-03-05 | — | — | EP | disclosed |
| EP-3997103-B9 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2025-02-26 | — | — | EP | disclosed |
| EP-3997103-B1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2024-11-20 | — | — | EP | disclosed |
| CN-118955620-A | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118930608-A | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2024-11-12 | — | — | CN | disclosed |
| WO-2024165072-A1 | POLYPEPTIDE COMPOUND AND USE THEREOF | 成都纽瑞特医疗科技股份有限公司 | 2024-08-15 | — | — | WO | disclosed |
| CN-114341159-B | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117736266-A | Preparation method and application of fibroblast activation protein specific diagnosis and treatment integrated probe | 上海交通大学医学院附属仁济医院 | 2024-03-22 | — | — | CN | disclosed |
| EP-4274835-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2023-11-15 | — | — | EP | disclosed |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-10-06 | — | — | US | disclosed |
| US-20220273831-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-09-01 | — | — | US | disclosed |
| WO-2022148843-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-07-14 | — | — | WO | disclosed |
| EP-3997104-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2022-05-18 | — | — | EP | disclosed |
| CN-114341159-A | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114341158-A | Compounds comprising fibroblast activation protein ligands and uses thereof | 3B制药有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | MAPK8 763/4885MAPK9 669/4885MAPK10 1062/4885 |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | MAPK8 763/4885MAPK9 669/4885MAPK10 1062/4885 |
| US-20260061086-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FAP, FIBP, FGF23 | MAPK8 1456/4885MAPK9 1282/4885MAPK10 458/4885 |
| US-20220273831-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FGF2, FRS2 | MAPK8 1300/4885MAPK9 1235/4885MAPK10 1804/4885 |
| US-12427210-B2 | Compounds comprising a fibroblast activation protein ligand and use thereof | FIBP, FGF2, FRS2 | MAPK8 1300/4885MAPK9 1235/4885MAPK10 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.